Hypersecretion of calcitonin
ICD-10 E07.0 is a billable code used to indicate a diagnosis of hypersecretion of calcitonin.
Hypersecretion of calcitonin is a condition characterized by excessive production of calcitonin, a hormone produced by the parafollicular cells (C cells) of the thyroid gland. Calcitonin plays a crucial role in calcium homeostasis by lowering blood calcium levels through its actions on bone and kidney. This condition is often associated with medullary thyroid carcinoma, a type of thyroid cancer that arises from C cells. Patients may present with symptoms related to hypercalcemia, such as nausea, vomiting, abdominal pain, and neurological disturbances. Diagnosis typically involves measuring serum calcitonin levels, which can be significantly elevated in affected individuals. Thyroid function tests, including TSH, T3, and T4 levels, are essential to rule out other thyroid disorders such as hyperthyroidism or hypothyroidism. Management may include surgical intervention, particularly if a neoplasm is present, and monitoring of calcitonin levels postoperatively. Understanding the interplay between calcitonin secretion and other thyroid hormones is vital for accurate diagnosis and treatment.
Detailed lab results, imaging studies, and clinical notes on symptoms and treatment plans.
Patients presenting with elevated calcitonin levels, thyroid nodules, or symptoms of hypercalcemia.
Ensure comprehensive documentation of all thyroid function tests and any imaging studies performed.
Pathology reports, surgical notes, and follow-up care documentation.
Patients diagnosed with medullary thyroid carcinoma and undergoing treatment.
Accurate staging and documentation of cancer type are crucial for coding.
Used to confirm diagnosis of hypersecretion of calcitonin.
Document the reason for the test and any relevant clinical findings.
Endocrinologists should ensure comprehensive lab results are included in the patient's record.
Common symptoms include nausea, vomiting, abdominal pain, and neurological disturbances due to hypercalcemia.
Diagnosis is made through elevated serum calcitonin levels, imaging studies, and possibly biopsy to confirm the presence of medullary thyroid carcinoma.
